COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Completed · Phase 1
Conditions studied: Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
In brief
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Key facts
- Study ID
- NCT03667716
- Run by
- Compugen Ltd
- People needed
- 121
- Starts
- 2018-09-06
- Expected to finish
- 2024-01-30
- Last updated by the study team
- 2025-01-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Los Angeles (UCLA). — Los Angeles, California, United States
- Florida Cancer Specialists — Sarasota, Florida, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- START Midwest. — Grand Rapids, Michigan, United States
- Columbia University — New York, New York, United States
- Cleveland Clinic. — Cleveland, Ohio, United States
- The University of Tennessee WEST Cancer Center. — Memphis, Tennessee, United States
- Sarah Cannon Research Institute. — Nashville, Tennessee, United States
- M D Anderson Cancer Center. — Houston, Texas, United States
- The START Center for Cancer Care. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.